Fig. 2From: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplantComparison of outcomes after complete remission between study group and historical group. a Cumulative incidence of re-relapse after complete remission. b Leukemia-free survival (LFS) after complete remission. c Survival after complete remission. From January 1, 2013, to February 28, 2015, consecutive 47 patients received multiple consolidation chemotherapy and DLI and were finally included in study group. From January 1, 2000, to December 31, 2008, 34 patients only received induction chemotherapy plus DLI and were finally defined as historical groupBack to article page